Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
68.2M
-
Shares change
-
-2.72M
-
Total reported value, excl. options
-
$273M
-
Value change
-
-$9.53M
-
Put/Call ratio
-
1.72
-
Number of buys
-
53
-
Number of sells
-
-26
-
Price
-
$4.00
Significant Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q3 2025
113 filings reported holding ADCT - ADC Therapeutics SA - Common Shares as of Q3 2025.
ADC Therapeutics SA - Common Shares (ADCT) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 68.2M shares
of 124M outstanding shares and own 54.94% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (15.7M shares), Point72 Asset Management, L.P. (8.14M shares), Prosight Management, LP (7.47M shares), ORBIMED ADVISORS LLC (5.91M shares), BlackRock, Inc. (4.51M shares), MORGAN STANLEY (3.67M shares), Nantahala Capital Management, LLC (2.27M shares), GOLDMAN SACHS GROUP INC (1.59M shares), TCG Crossover Management, LLC (1.39M shares), and BANK OF AMERICA CORP /DE/ (1.36M shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.